KEY TAKEAWAYS
- The study aimed to investigate the efficacy of combining enzalutamide with radium-223 therapy in patients with CRPC and bone metastases.
- Researchers observed that combining enzalutamide with radium-223 therapy improves outcomes in CRPC with bone metastases.
Radium-223 therapy has been reported to improve prognosis in patients with castration-resistant prostate cancer (CRPC) and bone metastases. However, the efficacy of combining radium-223 with androgen receptor signaling inhibitors (ARSIs) like enzalutamide remains unclear.
Naoto Wakita and the team aimed to evaluate the effectiveness of adding enzalutamide to radium-223 therapy in patients with CRPC.
Researchers conducted an inclusive analysis involving patients diagnosed with CRPC and bone metastases who received radium-223 treatment at the institution. Patients were allocated to either the enzalutamide combination group or the non-combination group. Progression-free survival (PFS), overall survival (OS), and the completion rate of radium-223 were compared between the 2 groups.
About 39 patients diagnosed with CRPC were included in this retrospective study, with a median follow-up duration of 8.8 months. The enzalutamide combination and non-combination groups comprised 22 (56.4%) and 17 patients (43.6%), respectively.
Median PFS was 11.3 months [95% confidence interval (CI)=3.9-19.9] in the combination group and 3.0 months (95% CI=1.9-5.5) in the non-combination group (P=0.004). Median OS did not significantly differ between the groups. The radium-223 completion rate was higher in the combination group compared to the non-combination group (72.7% vs. 35.3%, P=0.026).
The study concluded that the combined administration of enzalutamide with radium-223 therapy resulted in enhanced PFS and increased treatment completion rates among patients diagnosed with CRPC and bone metastases. This combination therapy holds promise for potentially improving the overall prognosis of these patients.
No funding information was provided.
Source: https://pubmed.ncbi.nlm.nih.gov/38821616/
Wakita N, Hara T, Suzuki K, et al. (2024). “Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.” Anticancer Res. 2024 Jun;44(6):2627-2635. doi: 10.21873/anticanres.17069. PMID: 38821616.
